Clinical Trials · NCT04657016
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 579
- Start date
- Mar 2021
- Locations
- 65 sites, 4 countries
- Primary endpoint
- Percent Change From Baseline in Body Weight